PASG - Passage Bio Inc. Market Capitalization-to-Revenue Ratio
Passage Bio, Inc. (PASG) relies on AAV vector patents and powerful lobbying under strict FDA oversight. Therapy safety is ensured by cryogenic supply chain logistics. Narrow CNS niches create a defensive moat, despite the binary risks of clinical trials. The current P/S ratio visualizes these fundamentals, while the value determines the metric's magnitude, capturing valuation deviations from the norm.
Passage Bio, Inc. (PASG) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Debt to Capital Passage Bio, Inc.|PASG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital passagebio.com|PASG - Company Aggregate Debts|Debts to Net Assets Passage Bio Corp|PASG - Company Long-Term Debt|Company Short-Term Indebtedness Passage Bio|Quick Liquidity Indicator passagebio.com
- financial results and valuation multiples details:
PASG - Net Income|Company Profit Forecast Passage Bio, Inc.|PASG - Price to Earnings Ratio|Price to Expected Earnings Ratio passagebio.com|PASG - PEG Multiple|EV/EBITDA Multiple Passage Bio Corp|PASG - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Passage Bio|PASG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year passagebio.com|PASG - Earnings per share growth in current year|Projected earnings per share growth rate for next year Passage Bio, Inc.
- issuer revenue and sales details:
General company analysis:PASG, Passage Bio Inc.
An investment audit of the issuer requires a thorough assessment of market value relative to actual earnings before purchasing assets. This metric is calculated as the ratio of Passage Bio, Inc. (PASG) market capitalization to its total revenue, measuring the premium the market is willing to pay per unit of sales. For this gene therapy developer, this ratio reflects the risks of commercialization delays caused by geopolitical barriers in clinical trials. Analyzing the price-to-sales ratio allows for a balance between expected returns and regulatory threats.
Competitors of Passage Bio, Inc.
BIIB - Price to Sales|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|ACAD: Price-to-Revenue Ratio|XENE: P/S Multiple|VKTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Supernus|Price to Sales Catalyst Pharma CPRX|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BHVN (Biohaven Ltd.)|Price-to-Revenue Coefficient amylyx.com (AMLX)|TRVI - Price-to-Revenue Ratio|PRAX (Praxis Precision Medicines Inc) - Market Cap to Revenue Ratio|AVXL: P/S Multiple|Market Cap to Revenue CeriBell EEG|Market Cap to Revenue PRTA|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Annexon (ANNX)|OMER: Price-to-Sales Ratio|P/S Multiple NGNE (Neurogene Corp)|P/S Multiple AC Immune Inc ACIU|VYGR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient neumoratx.com NMRA|SCLX: P/S Multiple|Price-to-Revenue Multiple Tevogen Bio Holdings Inc. TVGN|Price-to-Revenue Ratio Alpha Cognition Inc|Market Cap to Revenue Ratio CGTX (Cognition Therapeutics Inc.)|P/S Multiple IKT|SAVA - Price to Sales|Assertio - Market Cap to Revenue|P/S Multiple Coya Therapeutics Inc COYA|VTGN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OVID (Ovid Therapeutics Inc.)|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|Price to Sales cervomed.com (CRVO)|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine - Price-to-Sales Ratio|P/S Multiple PEPG|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics RLMD|Price-to-Revenue Coefficient annovisbio.com (ANVS)|GRCE - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Firefly Neuroscience, Inc. AIFF|KLTO: P/S Multiple|NeuroSense Therapeutics Ltd. (NRSN) - P/S Multiple|RVPH (Reviva Pharmaceuticals) - P/S Multiple|MTVA - Price-to-Revenue Multiple|P/S Multiple NRXS|HSDT - Price to Sales|Neuphoria Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NERV|Athira Pharma, Inc. - P/S Multiple|ADXN: Price-to-Revenue Ratio|ALZN: P/S Multiple|CYCN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Price to Sales Pasithea KTTA|Market Cap to Revenue CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Price-to-Revenue Coefficient Cara Therapeutics Inc. (CARA)|CHRO - Price-to-Revenue Ratio|ELYM (Eliem Therapeutics) - Market Cap to Revenue Ratio|ITCI: P/S Multiple|Market Cap to Revenue longboardpharma.com|Market Cap to Revenue MRNS|NKGen Biotech Inc (NKGN) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE: Price-to-Sales Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|P/S Multiple trevena.com TRVN|VIGL - Price-to-Revenue Ratio|Price-to-Revenue Coefficient anewmeds.com WENA|CERE: P/S Multiple
